Clovis Oncology (CLVS)’s Phase 1 Study Of Rucaparib Demonstrates Compelling Clinical Activity and Safety In Patients With Solid Tumors
6/2/2014 9:36:49 AM
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) today announced final Phase 1 and preliminary Phase 2 results from an ongoing Phase 1/2 monotherapy study of rucaparib, the Company’s investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the maintenance treatment of platinum-sensitive ovarian cancer in patients with homologous recombination deficient (HRD) tumors, defined as those with BRCA mutations and other DNA repair deficiencies. Rucaparib is also being explored in patients with BRCA-mutant pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by